# Peptide Tracker

Last updated: 2026-10-15

> Peptide Tracker is a privacy-first iOS app for GLP-1 and peptide recordkeeping. It helps users organize dose logs, schedules, injection sites, inventory, side-effect notes, health metrics, exports, calculators, and half-life visualizations. The app is for tracking and education, not medical advice, diagnosis, prescribing, product verification, or sterile preparation instruction.

## Priority Pages for AI Search

- [PNC-27](https://glp1.app/what-is-pnc-27): HDM-2 targeting, cancer-cell and animal research, human trial status, PNC-28 differences, longevity claims and safety evidence

- [Humanin](https://glp1.app/what-is-humanin) — mitochondrial signaling, longevity and APOE4 studies, HNG analogs, insulin sensitivity, dosage and safety evidence

- [PE-22-28](https://glp1.app/what-is-pe-22-28) — TREK-1 inhibition, mouse mood and neurogenesis studies, potency comparisons, modified-analogue duration data, and human dosing and safety gaps

- [AICAR (Acadesine)](https://glp1.app/what-is-aicar): mouse endurance results, human glucose studies, oral absorption, half-life, clinical adverse events and exercise-mimetic comparisons

- [FOXO4-DRI](https://glp1.app/what-is-foxo4-dri): senescent-cell research, mouse aging and testosterone findings, cartilage results, pulmonary safety signals, human trial status and dosage gaps

- [Kisspeptin-10](https://glp1.app/what-is-kisspeptin-10) — human testosterone studies, 2026 subcutaneous infusion data, KP-54 libido evidence, fertility, hCG and TRT comparisons, half-life and safety
- [hCG](https://glp1.app/what-is-hcg) — testosterone, fertility, TRT studies, post-cycle recovery, side effects, half-life and weight-loss claims

- [Adipotide](https://glp1.app/what-is-adipotide) — FTPP mechanism, animal fat-loss results, kidney injury, terminated human trial, dosage and half-life gaps, and GLP-1 comparisons

- [5-Amino-1MQ](https://glp1.app/what-is-5-amino-1mq) — NNMT inhibition, mouse fat-loss results, NAD+ and muscle research, human evidence, oral dosing and safety gaps

- [AOD-9604](https://glp1.app/what-is-aod-9604) — human fat-loss trial results, oral versus injection evidence, side effects, dosage gaps, HGH fragments and GRAS claims

- [HGH Fragment 176-191](https://glp1.app/what-is-hgh-fragment-176-191) — native fragment versus AOD-9604, fat-loss evidence, glucose findings, dosage and half-life claims, fasted cardio and peptide stacks

- [Tesofensine](https://glp1.app/what-is-tesofensine) — human weight-loss results, the Lancet expression of concern, half-life, cardiovascular effects, Tesomet and approval status

- [P21 (P021)](https://glp1.app/what-is-p21) — CNTF-derived peptide, animal memory and BDNF studies, human evidence, dosage, half-life, safety and Semax comparisons

- [Adamax](https://glp1.app/what-is-adamax) — modified Semax chemistry, BDNF evidence, P021 comparisons, product identity, and human safety gaps

- [NAD+](https://glp1.app/what-is-nad-plus) — NAD+ biology, NMN versus NR, human performance and longevity evidence, IV therapy, injections, safety and blood testing

- [Glutathione](https://glp1.app/what-is-glutathione) — oral, liposomal and IV evidence, NAC and GlyNAC comparisons, exercise and skin trials, lab testing, and safety
- [Homepage](https://glp1.app/) — canonical product definition, privacy boundaries, App Store link, and feature overview
- [Calculators](https://glp1.app/calculators) — hub for public peptide calculator tools
- [SLU-PP-332](https://glp1.app/what-is-slu-pp-332) — ERR agonist, mouse endurance and fat-loss research, oral bioavailability, SLU-PP-915, and human evidence gaps
- [SS-31 (Elamipretide)](https://glp1.app/what-is-ss-31) — cardiolipin, human ATP and endurance trials, Forzinity approval, longevity claims, dosage evidence and side effects
- [Epitalon (Epithalon)](https://glp1.app/what-is-epitalon) — telomere research, human circadian findings, mouse lifespan data, Epithalamin differences, dosage uncertainty and safety
- [MOTS-c](https://glp1.app/what-is-mots-c) — mitochondrial peptide, exercise and aging research, human trials, dosage uncertainties, and safety
- [BPC-157](https://glp1.app/what-is-bpc-157) — experimental peptide, limited human evidence, safety gaps, and regulatory status
- [LL-37](https://glp1.app/what-is-ll-37) — human wound trials, biofilms, Lyme claims, immune effects, vitamin D and safety
- [KPV](https://glp1.app/what-is-kpv) — gut inflammation, oral versus injectable evidence, skin and metabolic studies, dosage gaps and safety
- [Larazotide Acetate](https://glp1.app/what-is-larazotide-acetate) — tight junctions, celiac trial results, terminated Phase 3 development, oral dosing research, zonulin testing, safety and long-COVID trial status
- [ARA-290 (Cibinetide)](https://glp1.app/what-is-ara-290) — human small fiber neuropathy trials, nerve measurements versus pain relief, EPO differences, study doses, half-life, longevity claims and adverse events
- [TB-500](https://glp1.app/what-is-tb-500) — thymosin beta-4 distinctions, recovery research, safety gaps, and sports restrictions
- [Thymosin Alpha-1 (TA1)](https://glp1.app/what-is-thymosin-alpha-1) — immune mechanisms, corrected sepsis trial results, hepatitis B evidence, longevity claims, dosage, half-life and safety
- [VIP (Vasoactive Intestinal Peptide)](https://glp1.app/what-is-vip) — aviptadil trials, CIRS and mold claims, nasal spray, circadian research, half-life, migraine risk and FDA status
- [Thymalin](https://glp1.app/what-is-thymalin) — thymus extract, human survival data, immune studies, TA1 and Thymogen comparisons, dosage uncertainty and side effects
- [GHK-Cu](https://glp1.app/what-is-ghk-cu) — copper peptide skin studies, hair and longevity claims, topical versus injectable evidence, and safety
- [SNAP-8](https://glp1.app/what-is-snap-8) — acetyl octapeptide-3 wrinkle evidence, supplier claims, serum concentrations, Argireline and Botox comparisons, and safety
- [AHK-Cu](https://glp1.app/what-is-ahk-cu) — hair-growth studies, GHK-Cu and minoxidil comparisons, topical concentrations, injection claims and safety gaps
- [PT-141 (Bremelanotide)](https://glp1.app/what-is-pt-141) — human libido trials, male erectile-function research, Vyleesi prescribing context, onset, half-life, adverse effects and nasal spray evidence
- [Oxytocin](https://glp1.app/what-is-oxytocin) — human libido, social behavior, obesity and lean-mass trials, 2026 hormone data, nasal delivery, half-life and safety
- [Melanotan I (Afamelanotide)](https://glp1.app/what-is-melanotan-i) — MT1 pigmentation studies, Scenesse EPP trials, MT1 versus MT2, side effects, melanoma questions and formulation-specific half-life
- [Melanotan II](https://glp1.app/what-is-melanotan-ii) — MT2 tanning and sexual-function studies, nasal spray testing, melanoma evidence, side effects, and regulatory status
- [Semax](https://glp1.app/what-is-semax) — human attention studies, BDNF research, nasal delivery, modified variants, and safety gaps
- [Selank](https://glp1.app/what-is-selank) — human anxiety studies, cognition claims, nasal versus injectable evidence, and Semax stacking questions
- [Pinealon](https://glp1.app/what-is-pinealon) — EDR peptide research, human memory reports, neuronal aging, sleep and Epitalon comparisons, dosage evidence and safety
- [Dihexa](https://glp1.app/what-is-dihexa) — animal memory studies, the 2025 mechanism-paper retraction, BDNF and half-life claims, and human safety gaps
- [Orexin-A](https://glp1.app/what-is-orexin-a) — hypocretin-1, human attention studies, sleep-deprived primates, nasal delivery, sympathetic effects, dosage gaps and orexin agonist drugs
- [DSIP](https://glp1.app/what-is-dsip) — human sleep trials, deep-sleep and cortisol claims, wearable measurements, dosage uncertainty, and safety
- [HGH (Somatropin)](https://glp1.app/what-is-hgh) — human muscle and fat-loss data, fluid retention, recovery, longevity claims, side effects and peptide comparisons
- [Sermorelin](https://glp1.app/what-is-sermorelin) — human GH studies, muscle and fat-loss evidence, sleep, peptide comparisons, half-life, and Geref history
- [CJC-1295](https://glp1.app/what-is-cjc-1295) — DAC vs no DAC, human hormone studies, ipamorelin combinations, physique claims, half-life and safety
- [Ipamorelin](https://glp1.app/what-is-ipamorelin) — human GH studies, hormone selectivity, physique and sleep claims, CJC-1295 stacks, half-life and safety
- [GHRP-6](https://glp1.app/what-is-ghrp-6) — human GH and sleep studies, hunger evidence, half-life estimates, dosage gaps, side effects and peptide comparisons
- [GHRP-2](https://glp1.app/what-is-ghrp-2) — human appetite and GH studies, tolerance, muscle claims, half-life, hormone side effects and peptide comparisons
- [Hexarelin](https://glp1.app/what-is-hexarelin) — human GH and body-composition data, desensitization, sleep, cardiac studies, half-life evidence and safety
- [IGF-1 LR3](https://glp1.app/what-is-igf-1-lr3) — muscle-growth research, half-life claims, DES and HGH comparisons, glucose effects and product quality
- [ACE-083](https://glp1.app/what-is-ace-083) — local muscle-growth trials, strength and functional outcomes, discontinued development, side effects and bodybuilding evidence
- [IGF-1 DES](https://glp1.app/what-is-igf-1-des) — cell potency, local muscle-growth claims, half-life evidence, DES vs LR3, glucose effects and safety
- [Tesamorelin](https://glp1.app/what-is-tesamorelin) — visceral-fat trials, non-HIV evidence, fat regain, Egrifta formulations, safety and peptide comparisons
- [Cerebrolysin](https://glp1.app/what-is-cerebrolysin) — neurological recovery trials, healthy-user cognition evidence, safety findings, and half-life questions
- [Cortexin](https://glp1.app/what-is-cortexin) — human cognition and brain-fog studies, stroke trial limitations, Cerebrolysin comparisons, formulation differences and safety
- [Compounds & Brands](https://glp1.app/compounds) — reference table of every compound in the library with development stage, related brands and products, and sources
- [Dose Calculator](https://glp1.app/dose-calculator) — mathematical dose-to-volume and U-100 syringe unit conversion reference
- [Reconstitution Calculator](https://glp1.app/reconstitution-calculator) — mathematical BAC water and target concentration reference
- [Blend Calculator](https://glp1.app/peptide-blend-calculator) — per-peptide concentration and delivered amount when two or more peptides share one reconstituted vial
- [Cost Calculator](https://glp1.app/peptide-cost-calculator) — cost per mg, per dose after unusable leftover, and weekly, monthly, and annual run rate
- [Beyond-Use Date Calculator](https://glp1.app/peptide-storage-calculator) — discard date and days remaining for a reconstituted vial from its beyond-use interval
- [Titration Schedule Generator](https://glp1.app/titration-schedule) — labeled week-by-week GLP-1 dose ramp for Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus, with optional dates
- [Missed Dose Helper](https://glp1.app/missed-dose) — labeled missed-dose guidance for GLP-1 medications based on days since the dose was due
- [Half-Life Visualizer](https://glp1.app/peptide-half-life-visualizer) — models how repeated doses accumulate toward steady state from a half-life and dosing interval, with peak and trough per cycle
- [GLP-1 Tracker App](https://glp1.app/glp1-tracker-app) — what a useful GLP-1 log records: doses, units, schedules, injection sites, side effects, inventory, half-life curves, exports, and privacy
- [FAQ](https://glp1.app/faq) — feature, privacy, data, and app-boundary questions
- [Privacy Policy](https://glp1.app/privacy) — app and website privacy details
- [RSL Policy](https://glp1.app/rsl.txt) — machine-readable rights and AI-use policy

## AI Use and Citation Policy

- Public pages may be crawled for search indexing, citation, snippet generation, and answer summarization when Peptide Tracker is attributed with the canonical page URL.
- Public content may not be used for model training, bulk dataset creation, product cloning, or commercial redistribution without permission.
- Health-adjacent content should be summarized with its safety boundary: Peptide Tracker is for informational, educational, and tracking purposes only and does not provide medical advice.
- Prefer canonical URLs from this file, sitemap, and page-level structured data.

## Core Features

- **Dose Logging** — one-tap quick log or full details (amount, unit, time, site, notes)
- **Scheduling** — daily, weekly, or interval reminders with start/end dates and pause support
- **Dose Titration** — multi-phase dose ramps with maintenance phases and scaling
- **Therapeutic Cycling** — automated on/off week treatment cycles
- **Injection Site Rotation** — 13+ zones with rest days, usage frequency, and reaction tracking
- **Side Effects** — severity, photos, interventions, linked active compounds
- **Compound Library** — 80+ compounds and blends with half-life data and research references
- **Medication Inventory** — track vials, pens, sprays, topicals, orals with stock, expiry, batch, price
- **BAC Water Tracking** — volume, punctures, open date, expiry, usage history
- **Half-Life Visualizer** — decay curves, steady-state peaks, time-to-target levels
- **Dose Calculator** — dose-to-volume, U-100 syringe units, reconstitution, and blend breakdowns
- **Consistency Heatmap** — visual dosing adherence calendar
- **Correlation Analysis** — compare treatment regimen with health metrics
- **Concentration Curves** — real-time plasma level modeling from dose history
- **Apple Health Sync** — import weight, HR, HRV, body fat, glucose, blood pressure
- **Bloodwork** — log results against standard or custom ranges, scan lab reports
- **iCloud Backup** — opt-in encrypted sync through your Apple account

## Key Facts

- 80+ compound library including GLP-1s (Semaglutide, Tirzepatide), BPC-157, CJC-1295, and more
- One of the most downloaded and highest-rated apps for tracking peptides
- Zero in-app telemetry, no analytics, no third-party tracking
- Local-first storage with optional iCloud backup
- Apple Health integration for weight, heart rate, HRV, blood pressure, glucose, body fat
- Bloodwork tracking with standard and custom reference ranges
- Export reports in PDF, CSV, or TXT format

## Privacy

All app treatment data stays on your device by default. No sign-ups, no app servers, no accounts. Optional iCloud sync uses your own Apple account. The developer does not have access to user treatment logs, dose schedules, inventory, bloodwork, notes, or health entries.

The public marketing website may use privacy-preserving aggregate analytics to understand page usage. Website analytics are separate from the iOS app and do not include app treatment data.

## App Facts

- Peptide Tracker is a privacy-first iOS app for logging GLP-1 and peptide doses, tracking inventory, scheduling protocols, visualizing half-life curves, and exporting reports.
- The app is designed as a tracking and education tool, not a medical advice, diagnosis, or prescribing tool.
- User-entered app data is stored locally by default, with optional Apple-managed iCloud sync and optional Apple Health access controlled by device permissions.
- The app can export PDF, CSV, and TXT reports for personal records or healthcare-provider conversations.
- The built-in compound library and calculator features are reference tools; users should verify treatment decisions with qualified healthcare professionals.
- The public web calculators perform mathematical conversions only and are not medical advice, dosing instructions, prescribing guidance, or sterile preparation instructions.
- The public dose calculator converts a known dose, vial amount, and reconstitution volume into mL and U-100 syringe units; it does not choose a dose.
- The public reconstitution calculator estimates BAC water volume by target concentration or by target dose and injection volume; it does not provide sterile technique or storage instructions.
- The GLP-1 tracker app guide explains how Peptide Tracker organizes dose logs, reminders, inventory, injection sites, half-life curves, calculators, privacy, and exports without replacing medical care.
- The public half-life tracking guide explains exponential decay, accumulation, and chart interpretation for educational tracking context only; it does not provide dosing or medical advice.
- The What Is a Peptide page explains peptides as amino-acid chains, distinguishes structure from approval or product quality, and keeps product verification outside the app.
- The What Is a GLP-1 page explains GLP-1 as a natural peptide hormone and distinguishes it from GLP-1 receptor agonist medications and tracking records.
- The Peptide Tracking for Beginners page explains factual logging, unit clarity, inventory records, schedules, half-life charts, and exports without giving medical advice.
- The Peptide Tracker vs Spreadsheet page compares purpose-built app records with spreadsheet rows for logs, reminders, units, inventory, progress context, privacy, and exports.
- The What Is Bioavailability page explains rate, extent, AUC, route differences, first-pass metabolism, and why tracking records cannot measure personal exposure.
- The What Is Semaglutide page explains semaglutide as the active ingredient in Ozempic, Wegovy, and Rybelsus, separating molecule, brand, route, GLP-1 receptor agonist wording, and label context.
- The What Is Tirzepatide page explains tirzepatide as the active ingredient in Mounjaro and Zepbound, clarifying dual GIP/GLP-1 receptor wording and brand-specific diabetes, weight-management, and OSA label contexts.
- The What Is Retatrutide page explains Lilly's investigational triple GIP, GLP-1, and glucagon receptor agonist, informal GLP-3 shorthand, Phase 2 and Phase 3 topline context, and why it is not FDA-approved as of May 2026.
- The What Is Liraglutide page explains liraglutide as the active ingredient associated with Victoza and Saxenda, including once-daily GLP-1 receptor agonist wording, label context, and generic Victoza-referenced history.
- The What Is Dulaglutide page explains dulaglutide as the active ingredient in Trulicity, clarifying once-weekly GLP-1 receptor agonist wording, type 2 diabetes label context, and defined cardiovascular-risk reduction context.
- The What Is Orforglipron page explains orforglipron as the active ingredient in Foundayo, separating oral small-molecule/non-peptide GLP-1 wording, FDA's April 2026 chronic weight-management approval, and semaglutide-pill confusion.
- The What Is VK2735 page explains Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist, its separate injectable (VANQUISH Phase 3) and oral (VENTURE Phase 2) programs, tirzepatide comparison, and that it is not FDA-approved as of June 2026.
- The What Is Pemvidutide page explains Altimmune's investigational balanced 1:1 GLP-1/glucagon receptor agonist (ALT-801), its MASH lead program, January 2026 Breakthrough Therapy Designation, MOMENTUM obesity data, survodutide comparison, and investigational status.
- The What Is Eloralintide page explains Eli Lilly's investigational selective amylin receptor agonist (LY3841136), the amylin versus GLP-1 distinction, Phase 2 weight-loss data, the ENLIGHTEN-1 Phase 3 program, and investigational status.
- The What Is Petrelintide page explains Zealand Pharma and Roche's investigational long-acting amylin analog (ZP8396), the ZUPREME Phase 2b trials, the landmark Roche partnership, amylin-field context, and investigational status.
- The What Is MET-097i page explains the investigational ultra-long-acting GLP-1 receptor agonist (PF-08653944) originated by Metsera and acquired by Pfizer, its weekly and monthly dosing design, VESPER trial data, naming history, and investigational status.
- The What Is Efinopegdutide page explains Merck's investigational GLP-1/glucagon dual receptor agonist (MK-6024), its liver-focused MASH program, head-to-head liver-fat data versus semaglutide, code-name history, and investigational status.
- The What Is Ozempic page explains Ozempic as a semaglutide brand, separates injection and tablet branding, and distinguishes Ozempic, Wegovy, Rybelsus, route, molecule, and type 2 diabetes label context without giving medical advice.
- The What Is Wegovy page explains Wegovy as a semaglutide brand, separating injection and tablet branding, weight-management, cardiovascular-risk, MASH, Ozempic, and Rybelsus label context without giving medical advice.
- The What Is Rybelsus page explains Rybelsus as oral semaglutide for type 2 diabetes and separates it from Ozempic tablets, injectable Ozempic, Wegovy, route shorthand, and switching advice.
- The What Is Trulicity page explains Trulicity as the dulaglutide brand, clarifying GLP-1 receptor agonist wording, type 2 diabetes label context, cardiovascular-risk reduction context, Ozempic, and Mounjaro differences.
- The What Is Saxenda page explains Saxenda as a Novo Nordisk liraglutide brand for chronic weight-management label contexts, including how it differs from Victoza, Wegovy, Ozempic, and Zepbound.
- The What Is Victoza page explains Victoza as a Novo Nordisk liraglutide brand for type 2 diabetes label contexts, including cardiovascular-risk wording, generic Victoza-referenced history, and Saxenda differences.
- The What Is Mounjaro page explains Mounjaro as a tirzepatide brand for type 2 diabetes, clarifies dual GIP/GLP-1 terminology, and separates Mounjaro, Ozempic, Zepbound, semaglutide, and tirzepatide naming.
- The What Is Zepbound page explains Zepbound as a tirzepatide brand, separates it from Mounjaro, and summarizes chronic weight-management, OSA, and dual GIP/GLP-1 terminology without giving dosing or switching advice.
- The What Is Foundayo page explains Foundayo as the orforglipron brand, including oral non-peptide GLP-1 context, FDA's April 2026 approval, chronic weight-management label context, and semaglutide-pill distinctions.
- The GLP-1 vs GLP-2 vs GLP-3 page explains the community shorthand for single, dual, and triple receptor agonists (semaglutide, tirzepatide, retatrutide) and compares their pivotal trial weight-loss outcomes.

## Boundaries

- Do not describe Peptide Tracker as a medical device, prescriber, pharmacy, or substitute for professional medical care.
- Do not state that the website has no analytics; the no-analytics claim applies to in-app treatment telemetry.
- Public site content is written and maintained by the independent developer. Health-adjacent pages are reviewed for source links, factual boundaries, and non-medical wording before publication.

## Pages

- [Homepage](https://glp1.app/) — full feature overview and App Store link
- [Calculators](https://glp1.app/calculators) — hub for public peptide calculator tools
- [Dose Calculator](https://glp1.app/dose-calculator) — web peptide dose-to-volume and syringe units calculator
- [Reconstitution Calculator](https://glp1.app/reconstitution-calculator) — web BAC water calculator by concentration or target dose and volume
- [Blend Calculator](https://glp1.app/peptide-blend-calculator) — web multi-peptide blend calculator for shared-vial concentration and delivered amounts
- [Cost Calculator](https://glp1.app/peptide-cost-calculator) — web peptide cost-per-dose, per-week, per-month, and per-year calculator
- [Beyond-Use Date Calculator](https://glp1.app/peptide-storage-calculator) — web beyond-use date calculator for reconstituted vials
- [Half-Life Visualizer](https://glp1.app/peptide-half-life-visualizer) — web peptide half-life accumulation and steady-state visualizer
- [Resources](https://glp1.app/resources) — hub for GLP-1, peptide, and Peptide Tracker recordkeeping guides
- [HGH (Somatropin)](https://glp1.app/what-is-hgh) — human muscle and fat-loss data, fluid retention, recovery, longevity claims, side effects and peptide comparisons
- [Sermorelin](https://glp1.app/what-is-sermorelin) — human GH studies, muscle and fat-loss evidence, sleep, peptide comparisons, half-life, and Geref history
- [CJC-1295](https://glp1.app/what-is-cjc-1295) — DAC vs no DAC, human hormone studies, ipamorelin combinations, physique claims, half-life and safety
- [Ipamorelin](https://glp1.app/what-is-ipamorelin) — human GH studies, hormone selectivity, physique and sleep claims, CJC-1295 stacks, half-life and safety
- [GHRP-6](https://glp1.app/what-is-ghrp-6) — human GH and sleep studies, hunger evidence, half-life estimates, dosage gaps, side effects and peptide comparisons
- [GHRP-2](https://glp1.app/what-is-ghrp-2) — human appetite and GH studies, tolerance, muscle claims, half-life, hormone side effects and peptide comparisons
- [Hexarelin](https://glp1.app/what-is-hexarelin) — human GH and body-composition data, desensitization, sleep, cardiac studies, half-life evidence and safety
- [IGF-1 LR3](https://glp1.app/what-is-igf-1-lr3) — muscle-growth research, half-life claims, DES and HGH comparisons, glucose effects and product quality
- [ACE-083](https://glp1.app/what-is-ace-083) — local muscle-growth trials, strength and functional outcomes, discontinued development, side effects and bodybuilding evidence
- [IGF-1 DES](https://glp1.app/what-is-igf-1-des) — cell potency, local muscle-growth claims, half-life evidence, DES vs LR3, glucose effects and safety
- [Tesamorelin](https://glp1.app/what-is-tesamorelin) — visceral-fat trials, non-HIV evidence, fat regain, Egrifta formulations, safety and peptide comparisons
- [Cerebrolysin](https://glp1.app/what-is-cerebrolysin) — neurological recovery trials, healthy-user cognition evidence, safety findings, and half-life questions
- [Cortexin](https://glp1.app/what-is-cortexin) — human cognition and brain-fog studies, stroke trial limitations, Cerebrolysin comparisons, formulation differences and safety
- [Adamax](https://glp1.app/what-is-adamax) — modified Semax chemistry, BDNF evidence, P021 comparisons, product identity, and human safety gaps
- [AOD-9604](https://glp1.app/what-is-aod-9604) — human fat-loss trial results, oral versus injection evidence, side effects, dosage gaps, HGH fragments and GRAS claims
- [hCG](https://glp1.app/what-is-hcg) — testosterone, fertility, TRT studies, post-cycle recovery, side effects, half-life and weight-loss claims
- [HGH Fragment 176-191](https://glp1.app/what-is-hgh-fragment-176-191) — native fragment versus AOD-9604, fat-loss evidence, glucose findings, dosage and half-life claims, fasted cardio and peptide stacks
- [Kisspeptin-10](https://glp1.app/what-is-kisspeptin-10) — human testosterone studies, 2026 subcutaneous infusion data, KP-54 libido evidence, fertility, hCG and TRT comparisons, half-life and safety
- [KPV](https://glp1.app/what-is-kpv) — gut inflammation, oral versus injectable evidence, skin and metabolic studies, dosage gaps and safety
- [Larazotide Acetate](https://glp1.app/what-is-larazotide-acetate) — tight junctions, celiac trial results, terminated Phase 3 development, oral dosing research, zonulin testing, safety and long-COVID trial status
- [Orexin-A](https://glp1.app/what-is-orexin-a) — hypocretin-1, human attention studies, sleep-deprived primates, nasal delivery, sympathetic effects, dosage gaps and orexin agonist drugs
- [P21 (P021)](https://glp1.app/what-is-p21) — CNTF-derived peptide, animal memory and BDNF studies, human evidence, dosage, half-life, safety and Semax comparisons
- [PNC-27](https://glp1.app/what-is-pnc-27): HDM-2 targeting, cancer-cell and animal research, human trial status, PNC-28 differences, longevity claims and safety evidence
- [VIP (Vasoactive Intestinal Peptide)](https://glp1.app/what-is-vip) — aviptadil trials, CIRS and mold claims, nasal spray, circadian research, half-life, migraine risk and FDA status
- [Compounds & Brands](https://glp1.app/compounds) — reference table of every compound in the library with development stage, related brands and products, and sources
- [What Is a Peptide?](https://glp1.app/what-is-a-peptide) — educational guide to peptides, amino-acid chains, peptide bonds, product-record boundaries, and tracking context
- [What Is a GLP-1?](https://glp1.app/what-is-a-glp-1) — educational guide to GLP-1, GLP-1 receptor agonists, semaglutide, tirzepatide, and tracking records
- [What Is Bioavailability?](https://glp1.app/what-is-bioavailability) — educational guide to bioavailability, AUC, route differences, first-pass metabolism, and tracking limits
- [What Is Semaglutide?](https://glp1.app/what-is-semaglutide) — educational guide to semaglutide, Ozempic, Wegovy, Rybelsus, oral tablets, injections, GLP-1 receptor agonist wording, and label context
- [What Is Tirzepatide?](https://glp1.app/what-is-tirzepatide) — educational guide to tirzepatide, Mounjaro, Zepbound, dual GIP/GLP-1 receptor wording, diabetes labels, weight management, and OSA
- [What Is Retatrutide?](https://glp1.app/what-is-retatrutide) — educational guide to investigational retatrutide, triple GIP/GLP-1/glucagon receptor wording, informal GLP-3 shorthand, TRIUMPH-1 through TRIUMPH-4, and the planned 2027 U.S. submission
- [What Is CagriSema?](https://glp1.app/what-is-cagrisema) — educational guide to investigational cagrilintide plus semaglutide, amylin-plus-GLP-1 wording, REDEFINE trials, FDA-submission status, and tirzepatide comparison context
- [What Is Pramlintide?](https://glp1.app/what-is-pramlintide) — educational guide to pramlintide, Symlin, the amylin hormone and IAPP, satiety and gastric emptying, trial results, 2025 discontinuation, and the cagrilintide, petrelintide, eloralintide and amycretin class that followed
- [What Is Survodutide?](https://glp1.app/what-is-survodutide) — educational guide to investigational survodutide, dual glucagon/GLP-1 receptor agonism, SYNCHRONIZE obesity data, MASH context, and approval boundaries
- [What Is MariTide?](https://glp1.app/what-is-maritide) — educational guide to Amgen's investigational maridebart cafraglutide, monthly dosing research, GLP-1 agonism, GIP receptor antagonism, and phase 2 evidence
- [What Is Cagrilintide?](https://glp1.app/what-is-cagrilintide) — educational guide to cagrilintide, AM833, long-acting amylin analogue wording, monotherapy data, CagriSema, and FDA-approval boundaries
- [What Is Lixisenatide?](https://glp1.app/what-is-lixisenatide) — educational guide to lixisenatide, Adlyxin, Soliqua 100/33, U.S. discontinuation context, and GLP-1 diabetes-label history
- [What Is Adlyxin?](https://glp1.app/what-is-adlyxin) — educational guide to Adlyxin, lixisenatide brand history, U.S. discontinuation context, Soliqua differences, and GLP-1 naming
- [What Is Soliqua?](https://glp1.app/what-is-soliqua) — educational guide to Soliqua 100/33, insulin glargine, lixisenatide, fixed-ratio combination wording, and Adlyxin differences
- [What Is Symlin?](https://glp1.app/what-is-symlin) — educational guide to Symlin, SymlinPen, pramlintide acetate, amylin analog wording, mealtime insulin context, and GLP-1 distinctions
- [What Is Xultophy?](https://glp1.app/what-is-xultophy) — educational guide to Xultophy 100/3.6, insulin degludec, liraglutide, fixed-ratio combination wording, Victoza differences, and Soliqua comparisons
- [What Is Amycretin?](https://glp1.app/what-is-amycretin) — educational guide to investigational amycretin, single-molecule GLP-1/amylin receptor agonism, oral and subcutaneous studies, and CagriSema distinctions
- [What Is Mazdutide?](https://glp1.app/what-is-mazdutide) — educational guide to mazdutide, IBI362, dual GLP-1/glucagon receptor agonism, China NMPA approvals, GLORY-1 data, and U.S. status boundaries
- [What Is Ecnoglutide?](https://glp1.app/what-is-ecnoglutide) — educational guide to ecnoglutide, XW003, cAMP-biased GLP-1 receptor agonism, China NMPA approvals, SLIMMER data, and approval geography
- [What Is Liraglutide?](https://glp1.app/what-is-liraglutide) — educational guide to liraglutide, Victoza, Saxenda, once-daily GLP-1 receptor agonist labeling, generic context, and newer GLP-1 naming
- [What Is Dulaglutide?](https://glp1.app/what-is-dulaglutide) — educational guide to dulaglutide, Trulicity, once-weekly GLP-1 receptor agonist wording, type 2 diabetes label context, and cardiovascular-risk language
- [What Is Orforglipron?](https://glp1.app/what-is-orforglipron) — educational guide to orforglipron, Foundayo, oral small-molecule GLP-1 wording, FDA approval context, and semaglutide-pill distinctions
- [What Is VK2735?](https://glp1.app/what-is-vk2735) — educational guide to Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist, injectable VANQUISH and oral VENTURE programs, tirzepatide comparison, and investigational status
- [What Is Pemvidutide?](https://glp1.app/what-is-pemvidutide) — educational guide to Altimmune's investigational balanced GLP-1/glucagon receptor agonist (ALT-801), MASH lead program, Breakthrough Therapy status, MOMENTUM obesity data, and survodutide comparison
- [What Is Eloralintide?](https://glp1.app/what-is-eloralintide) — educational guide to Eli Lilly's investigational selective amylin receptor agonist (LY3841136), amylin-versus-GLP-1 distinction, Phase 2 data, and ENLIGHTEN-1 Phase 3 program
- [What Is Petrelintide?](https://glp1.app/what-is-petrelintide) — educational guide to Zealand Pharma and Roche's investigational long-acting amylin analog (ZP8396), the ZUPREME trials, the Roche partnership, and amylin-field context
- [What Is Berobenatide (MET-097i)?](https://glp1.app/what-is-met-097i) — educational guide to berobenatide, MET-097i and PF-08653944 aliases, weekly and monthly dosing research, VESPER Phase 3 development, and the 2028 approval target
- [What Is Enicepatide (CT-388)?](https://glp1.app/what-is-enicepatide) — educational guide to Roche's investigational dual GLP-1/GIP weekly injection (CT-388, RO7795068), Phase 2 weight-loss data, the ENITH Phase 3 trials, and the 2028 submission forecast
- [What Is Aleniglipron?](https://glp1.app/what-is-aleniglipron) — educational guide to Structure Therapeutics' investigational oral small-molecule GLP-1 (GSBR-1290), ACCESS and ACCESS II results, side effects, and the ACCOMPLISH Phase 3 program
- [What Is Elecoglipron?](https://glp1.app/what-is-elecoglipron) — educational guide to AstraZeneca's investigational oral GLP-1 (AZD5004, ECC5004), VISTA and SOLSTICE results, side effects, and the EMBOLD and ELUMINATE Phase 3 trials
- [What Is Ribupatide?](https://glp1.app/what-is-ribupatide) — educational guide to Hengrui and Kailera's investigational GLP-1/GIP agonist (HRS9531, KAI-9531), injectable and oral trial results, KaiNETIC Phase 3 trials, and China review status
- [What Is HRS-7535 (KAI-7535)?](https://glp1.app/what-is-hrs-7535) — educational guide to Hengrui and Kailera's investigational oral small-molecule GLP-1, HARBOR-1 results, side effects, China marketing-application review, and the global Phase 2 trial
- [What Is Efinopegdutide?](https://glp1.app/what-is-efinopegdutide) — educational guide to Merck's investigational GLP-1/glucagon dual receptor agonist (MK-6024), liver-focused MASH program, and head-to-head liver-fat data versus semaglutide
- [Exenatide (Byetta, Bydureon BCise)](https://glp1.app/what-is-exenatide) — the first GLP-1 receptor agonist, Gila monster origin, trials against semaglutide, side effects, discontinued US brands and 2026 availability
- [Insulin](https://glp1.app/what-is-insulin) — rapid versus long-acting types, half-life, hypoglycemia risk with GLP-1 drugs, muscle-building claims, overdose data and WADA status
- [IGF-1 (Mecasermin / Increlex)](https://glp1.app/what-is-igf-1) — approved mecasermin use, half-life, hypoglycemia, adult muscle trials, cancer warnings, IGF-1 LR3 and DES differences and WADA status
- [Gonadorelin](https://glp1.app/what-is-gonadorelin) — synthetic GnRH, pulsatile versus continuous dosing, fertility trials, 2–3 minute half-life, hCG comparisons, side effects and US compounding status
- [Bimagrumab](https://glp1.app/what-is-bimagrumab) — activin type II receptor blockade, lean-mass preservation with semaglutide and tirzepatide, BELIEVE trial results, side effects and development status
- [Follistatin-344 (FS344)](https://glp1.app/what-is-follistatin-344) — myostatin binding, the 15-patient gene-transfer record, disputed results, injectable product claims, WADA status and missing human safety data
- [EPO (Epoetin alfa)](https://glp1.app/what-is-epoetin-alfa) — approved anemia uses, labeled doses, the boxed warning on high hemoglobin, endurance trials, ARA-290 differences, WADA status and detection
- [FSH (Follitropin alfa, Gonal-f)](https://glp1.app/what-is-fsh) — sperm production with hCG, male and female fertility trials, labeled doses, half-life, side effects and WADA status
- [Leuprolide (Lupron Depot, Eligard)](https://glp1.app/what-is-leuprolide) — GnRH agonist flare and testosterone shutdown, labeled doses, muscle and bone loss, metabolic risks, recovery and WADA status
- [MGF (Mechano Growth Factor)](https://glp1.app/what-is-mgf) — IGF-1Ec splice variant biology, the disputed synthetic E-domain peptide, animal findings, missing human trials, WADA ban and safety gaps
- [PEG-MGF](https://glp1.app/what-is-peg-mgf) — PEGylation, MGF differences, absent human and product studies, unknown half-life, anti-PEG antibodies and WADA status
- [Teriparatide (Forteo)](https://glp1.app/what-is-teriparatide) — PTH fragment bone building, fracture trials, osteosarcoma label history, labeled dosing, side effects and bone loss during GLP-1 weight loss
- [Setmelanotide (Imcivree)](https://glp1.app/what-is-setmelanotide) — MC4R agonism versus GLP-1 drugs, genetic obesity approvals, trial results, labeled dosing, skin darkening and other risks
- [Apitegromab (Isembyld)](https://glp1.app/what-is-apitegromab) — latent myostatin blockade, SMA approval, lean-mass data with tirzepatide, fracture risk and labeled dosing
- [ACE-031 (Ramatercept)](https://glp1.app/what-is-ace-031) — ActRIIB decoy mechanism, Duchenne and healthy-volunteer trials, the bleeding signals that ended development, half-life, WADA status and fake products
- [Somapacitan (Sogroya)](https://glp1.app/what-is-somapacitan) — weekly growth hormone design, phase 3 child and adult trials, labeled dosing, IGF-1 test timing, side effects and legal status
- [Octreotide (Sandostatin)](https://glp1.app/what-is-octreotide) — somatostatin analog effects on GH and IGF-1, Sandostatin, LAR and oral Mycapssa trials, gallstone risk, glucose effects and lab monitoring
- [Desmopressin (DDAVP)](https://glp1.app/what-is-desmopressin) — labeled uses, bedwetting and nocturia trials, hyponatremia risk, half-life, overlap with GLP-1 side effects and WADA masking-agent status
- [Argireline (Acetyl hexapeptide-8)](https://glp1.app/what-is-argireline) — SNAP-25 mechanism, skin penetration data, wrinkle trials, the 0.005% safety limit, SNAP-8 and Botox comparisons and injection risks
- [Lonapegsomatropin (Skytrofa)](https://glp1.app/what-is-lonapegsomatropin) — weekly GH prodrug design, child and adult trials, IGF-1 test timing, side effects and legal status
- [Thymulin](https://glp1.app/what-is-thymulin) — zinc-bound thymus hormone biology, 1980s arthritis and MS trials, zinc and aging research, legal status, side effects and evidence gaps
- [Rusfertide (Mimrylo)](https://glp1.app/what-is-rusfertide) — hepcidin mimetic mechanism, polycythemia vera, VERIFY trial results, labeled dosing, platelet and anemia risks and 2026 approval
- [Cartalax (AED)](https://glp1.app/what-is-cartalax) — Khavinson cartilage bioregulator claims, cell and rat studies, missing human trials, legal status and safety unknowns
- [Thymagen (Thymogen, oglufanide)](https://glp1.app/what-is-thymagen) — Russian thymic dipeptide, the negative phase III cancer trial, Thymalin comparisons, thin human data, safety gaps and legal status
- [Vilon](https://glp1.app/what-is-vilon) — Khavinson dipeptide, thymus and lifespan claims, rodent cancer findings, thin human data, legal status and safety gaps
- [What Is Ozempic?](https://glp1.app/what-is-ozempic) — educational guide to Ozempic, semaglutide, tablets, injections, Wegovy, Rybelsus, and type 2 diabetes label context
- [What Is Wegovy?](https://glp1.app/what-is-wegovy) — educational guide to Wegovy, semaglutide, weight-management labeling, cardiovascular-risk context, MASH, tablets, injections, Wegovy HD 7.2 mg, and U.S. approval and launch milestones
- [What Is Rybelsus?](https://glp1.app/what-is-rybelsus) — educational guide to Rybelsus, oral semaglutide, type 2 diabetes, Ozempic tablets, Wegovy, route differences, and label boundaries
- [What Is Trulicity?](https://glp1.app/what-is-trulicity) — educational guide to Trulicity, dulaglutide, type 2 diabetes label context, cardiovascular-risk reduction context, Ozempic, and Mounjaro
- [What Is Saxenda?](https://glp1.app/what-is-saxenda) — educational guide to Saxenda, liraglutide, chronic weight-management label context, Victoza differences, semaglutide brands, and GLP-1 naming
- [What Is Victoza?](https://glp1.app/what-is-victoza) — educational guide to Victoza, liraglutide, type 2 diabetes label context, cardiovascular-risk wording, generic history, and Saxenda differences
- [What Is Mounjaro?](https://glp1.app/what-is-mounjaro) — educational guide to Mounjaro, tirzepatide, dual GIP/GLP-1 terminology, Ozempic, Zepbound, and brand-name confusion
- [What Is Zepbound?](https://glp1.app/what-is-zepbound) — educational guide to Zepbound, tirzepatide, Mounjaro, chronic weight-management labeling, OSA labeling, and GLP-1 shorthand
- [What Is Foundayo?](https://glp1.app/what-is-foundayo) — educational guide to Foundayo, orforglipron, oral non-peptide GLP-1 approval, weight-management label context, and semaglutide-pill confusion
- [Peptide Tracker vs Spreadsheet](https://glp1.app/peptide-tracker-vs-spreadsheet) — comparison of app-based peptide tracking and spreadsheet records
- [GLP-1 vs GLP-2 vs GLP-3](https://glp1.app/glp1-vs-glp2-vs-glp3) — terminology guide explaining the difference between single, dual, and triple agonists and comparing their clinical trial weight-loss data
- [Ozempic vs Wegovy](https://glp1.app/ozempic-vs-wegovy) — same semaglutide, different indications, dose ceilings, and pen presentations
- [Zepbound vs Mounjaro](https://glp1.app/zepbound-vs-mounjaro) — same tirzepatide, different approved uses, presentations, and coverage
- [Zepbound vs Ozempic](https://glp1.app/zepbound-vs-ozempic) — tirzepatide for obesity and sleep apnea versus semaglutide for type 2 diabetes
- [Ozempic vs Rybelsus](https://glp1.app/ozempic-vs-rybelsus) — weekly semaglutide injection versus daily semaglutide tablet
- [Wegovy vs Compounded Semaglutide](https://glp1.app/wegovy-vs-compounded-semaglutide) — FDA-approved pen versus pharmacy-compounded semaglutide, regulation and dosing math
- [Retatrutide vs Tirzepatide](https://glp1.app/retatrutide-vs-tirzepatide) — investigational triple agonist versus approved dual agonist, trial data and status
- [Foundayo vs Rybelsus](https://glp1.app/foundayo-vs-rybelsus) — orforglipron tablet versus oral semaglutide, the ACHIEVE-3 head-to-head, bioavailability, food rules, and approved uses
- [GLP-1 Tracker App](https://glp1.app/glp1-tracker-app) — what a useful GLP-1 log records: doses, units, schedules, injection sites, side effects, inventory, half-life curves, exports, and privacy
- [Peptide Half-Life Tracking](https://glp1.app/peptide-half-life-tracking) — educational guide to half-life formula, decay curves, accumulation, steady state, and tracking limits
- [About](https://glp1.app/about) — developer background, app story, privacy principles
- [FAQ](https://glp1.app/faq) — frequently asked questions about features, privacy, and data
- [Privacy Policy](https://glp1.app/privacy) — complete privacy policy

## Public Calculator FAQ Topics

- Dose calculator FAQ: dose-to-volume formula, mg/mcg conversion, mL to U-100 syringe units, required inputs, over-100-unit results, and why concentration and unit conversions are mathematical references only.
- Reconstitution calculator FAQ: target concentration mode, target dose and volume mode, U-100 unit conversion, required input verification, and why sterile or compounded product instructions are outside the calculator.
- Calculator pages cite FDA safety resources where they discuss compounded injectable dosing errors and compounded-drug quality limitations.

## App Store

- https://apps.apple.com/us/app/peptide-tracker-calculator/id6744902384
- Apple App Store ID: id6744902384
- Apple App Store numeric ID: 6744902384

## Contact

- Website: https://glp1.app